SC 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

SC 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

SC 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

RADNOR, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced the appointment of Minji Kim, Ph.D. as Chief Business Officer. Adam Levy will remain in his role as Chief Financial Officer. "With our expanding operations, we have decided to split the functions of Chief Financial Officer and Chief Business Officer into two roles, and we are excited to have Minji join our team. She brings a solid track record of generating value for multiple companies by identify

LOS ANGELES, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Praxis Bioresearch ("Praxis"), a biopharmaceutical company focused on the discovery and development of therapeutics for chronic neuropsychiatric and neurodegenerative disorders with an initial focus on apathy in Alzheimer's Disease, today announced the appointment of Adam Levy to its Board of Directors (the "Board"). Mr. Levy brings executive, financial and operational leadership experience in biopharmaceuticals. "We are excited to have Adam join our Board and support our mission to improve the lives of patients with Alzheimer's Disease," said Sandeep Patil, MD PhD, chief executive officer of Praxis Bioresearch. "Adam brings an impressive

4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

– Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025 – – Completed enrollment in Explore-CKD Phase 2 trial and anticipate delivering topline data in Q2 2025 – – Initiating Phase 2 trial to evaluate lorundrostat for the treatment of patients with moderate-to-severe obstructive sleep apnea (OSA) and hypertension – – Conference call today at 8:30 a.m. ET – RADNOR, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and oth

RADNOR, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2024, before the financial markets open on Wednesday, February 12, 2025. Wednesday, February 12th @ 8:30 a.m. ET Domestic:1-800-717-1738International:1-646-307-1865Webcast:Link A live webcast of the conference call may also be found on the "News & Events" page in the Investor Relati

RADNOR, Pa., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that it has completed enrollment in the Explore-CKD Phase 2 trial evaluating the efficacy and safety of lorundrostat for the treatment of hypertension in subjects with CKD and albuminuria, despite receiving stable treatment with an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB) and an SGLT2 inhibitor. "We are pleased to have comple

– Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions associated with excess morbidity and mortality – – Obstructive sleep apnea represents Mineralys' third precision, targeted indication for lorundrostat, further expanding its market potential in aldosterone-driven diseases – – Initiation of the trial anticipated in the first quarter of 2025 – RADNOR, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated a

– Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 – – Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering topline data in mid first half of 2025 – – Ongoing enrollment in Explore-CKD Phase 2 trial and anticipate delivering topline data in Q2 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced financial results fo

RADNOR, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in fireside chats at three upcoming investor conferences. Guggenheim Healthcare Innovation Conference:Date:Tuesday, November 12, 2024Time:4:00pm ESTFormat:Fireside ChatWebcast Link   Stifel Healthcare Conference:Date:Tuesday, November 19, 2024Time:10:20am ESTFormat:Fireside ChatWebcast Link   Evercore ISI HealthCONx ConferenceDate:Wednesday, December 4, 2024Time:4:15

RADNOR, Pa., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the third quarter ended September 30, 2024, after the financial markets close on Monday, November 11, 2024. Monday, November 11th @ 4:30 p.m. ET Domestic:1-877-407-9127International:1-201-689-8574Webcast:Link   A live webcast of the conference call may also be found on the "News & Events" page in the Investor Relations section of the Mineralys Therapeutics websi

– Topline data now anticipated in mid first half of 2025 – – Management to host virtual KOL event today to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal clinical program for lorundrostat in hypertension – RADNOR, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other prevalent cardiovascular diseases driven by dysregulated aldosterone, today announced that it has completed enrollment in the Launch-HTN trial ahead of schedule. Launch-HTN is the second of two trials under the planned pivota

RADNOR, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other prevalent cardiovascular diseases driven by dysregulated aldosterone, today announced full details for its upcoming virtual KOL event being held on Wednesday, October 30, 2024, at 10:00 AM ET. To register for the event, please click here. The event will feature comments from Luke J. Laffin, MD (Cleveland Clinic), James M. Luther, MD, MSCI (Vanderbilt University Medical Center), and Rhian Touyz, MBBCh, MSc (Med), PhD (McGill University Health Centre) who will each

– On track to announce topline data in Q1 2025 – – Virtual KOL event scheduled on October 30th to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal clinical program for lorundrostat in hypertension – RADNOR, Pa., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other prevalent cardiovascular diseases driven by dysregulated aldosterone, today announced that it has achieved the enrollment target of 261 subjects in the pivotal Advance-HTN trial evaluating the efficacy and safety of lorundrostat

H.C. Wainwright initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $30.00

Goldman initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $30.00

Evercore ISI initiated coverage of Mineralys Therapeutics with a rating of Outperform

BofA Securities initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $39.00

Guggenheim initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $32.00

Wells Fargo initiated coverage of Mineralys Therapeutics with a rating of Overweight and set a new price target of $27.00

Stifel initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $45.00

Credit Suisse initiated coverage of Mineralys Therapeutics with a rating of Outperform and set a new price target of $40.00

SCHEDULE 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

S-8 - Mineralys Therapeutics, Inc. (0001933414) (Filer)

10-K - Mineralys Therapeutics, Inc. (0001933414) (Filer)

8-K - Mineralys Therapeutics, Inc. (0001933414) (Filer)

8-K - Mineralys Therapeutics, Inc. (0001933414) (Filer)

144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)

144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)

8-K - Mineralys Therapeutics, Inc. (0001933414) (Filer)

S-8 - Mineralys Therapeutics, Inc. (0001933414) (Filer)

144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)

– Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025 – – Completed enrollment in Explore-CKD Phase 2 trial and anticipate delivering topline data in Q2 2025 – – Initiating Phase 2 trial to evaluate lorundrostat for the treatment of patients with moderate-to-severe obstructive sleep apnea (OSA) and hypertension – – Conference call today at 8:30 a.m. ET – RADNOR, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and oth

RADNOR, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2024, before the financial markets open on Wednesday, February 12, 2025. Wednesday, February 12th @ 8:30 a.m. ET Domestic:1-800-717-1738International:1-646-307-1865Webcast:Link A live webcast of the conference call may also be found on the "News & Events" page in the Investor Relati

– Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 – – Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering topline data in mid first half of 2025 – – Ongoing enrollment in Explore-CKD Phase 2 trial and anticipate delivering topline data in Q2 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced financial results fo

RADNOR, Pa., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the third quarter ended September 30, 2024, after the financial markets close on Monday, November 11, 2024. Monday, November 11th @ 4:30 p.m. ET Domestic:1-877-407-9127International:1-201-689-8574Webcast:Link   A live webcast of the conference call may also be found on the "News & Events" page in the Investor Relations section of the Mineralys Therapeutics websi

– Advance-HTN trial is approximately 90% enrolled; trial is anticipated to deliver topline data in Q1 2025 – – Enrollment ahead of schedule in Phase 3 pivotal Launch-HTN trial and on track to deliver topline data as anticipated in 2H 2025 – – Ongoing Explore-CKD Phase 2 trial is ramping up enrollment under the amended protocol and is anticipated to deliver topline data in 1H 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldost

RADNOR, Pa., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the second quarter ended June 30, 2024, after the financial markets close on Tuesday, August 13, 2024. Tuesday, August 13th @ 4:30 p.m. ETDomestic:1-877-407-9127International:1-201-689-8574Webcast:Link   A live webcast of the conference call may be found here or on the "News & Events" page in the Investor Relations section of the Mineralys Therapeutics websi

– Advance-HTN trial of lorundrostat for the treatment of uHTN or rHTN is anticipated to deliver topline data in Q4 2024 – – Ongoing Phase 3 pivotal Launch-HTN trial of lorundrostat for the treatment of uHTN or rHTN is anticipated to deliver topline data in 2H 2025 – – Ongoing Explore-CKD Phase 2 trial is anticipated to deliver topline data in Q4 2024 to Q1 2025 – – Conference call today at 8:30 a.m. ET – RADNOR, Pa., May 09, 2024 (GLOBE NEWSWIRE) --  Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announ

RADNOR, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2024, before the financial markets open on Thursday, May 9, 2024. Thursday, May 9th @ 8:30 a.m. ETDomestic:1-888-886-7786International:1-416-764-8658Conference ID:93715931Webcast:Link   Participants can use the dial-in information above or choose the Call me™ option (click here) for instant telephone access to the event which will

 – Enrollment in the two pivotal trials of lorundrostat for the treatment of uHTN or rHTN is on track, with topline data expected for Advance-HTN trial in Q4 2024 and Launch-HTN trial in 2H 2025 – – Explore-CKD Phase 2 trial, a study for lorundrostat in hypertensive patients with stage 2-3b CKD on track for Q4 2024 to Q1 2025 topline data – – Conference call today at 8:30 a.m. ET – RADNOR, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced financial re

RADNOR, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2023, before the financial markets open on Thursday, March 21, 2024. Thursday, March 21st @ 8:30 a.m. ET Domestic:1-888-886-7786International:1-416-764-8658Conference ID:27947513Webcast:Link   Participants can use the dial-in information above or choose the Call me™ option (click here) for instant telepho